CoChat
Sign Up
Cited by 56Antibiotics Pharmacokinetics and EfficacyAntibiotic Use and ResistanceAntibiotic Resistance in Bacteria

A Systematic Review and Meta-analysis of Antibiotic Treatment Duration for Bacteremia Due to Enterobacteriaceae

Open access
Tansarli, Giannoula S., Andreatos, Nikolaos, Pliakos, Elina E., Mylonakis, Eleftherios·2019·Antimicrobial Agents and Chemotherapy
DOI 10.1128/aac.02495-18PMC PMC6496097
Open this paper in CoChat — free account

Abstract

The duration of antibiotic therapy for bacteremia due to Enterobacteriaceae is not well defined. We sought to evaluate the clinical outcomes with shorter- versus longer-course treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.02495-18

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Extended and continuous infusions occupy a venous catheter/lumen more than intermittent infusion, and drug-stability and drug-drug compatibility considerations are important to ensure effectiveness of antibiotic and other IV drug therapies.

    “Over the course of therapy, both extended and continuous infusions will occupy a venous catheter/lumen more than an intermittent infusion and drug-stability and drug-drug compatibility considerations are important to ensure effectiveness of antibiotic and other IV drug therapies (235).”

    From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [235]

    The Introduction and Discussion address the duration of antibiotic treatment for Enterobacteriaceae bacteremia, not how infusions occupy a catheter lumen. Searches for extended or continuous infusion, drug stability, and IV-drug compatibility found no passage addressing those claims in our copy. No page numbers were provided for the passages. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 39

  1. [1]Goto M, Al-Hasan MN. 2013. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clin Microbiol Infect 19:501–509. doi: 10.1111/1469-0691.12195. [DOI] [PubMed] [Google Scholar] · DOI
  2. [2]National Center for Health Statistics. 2015. Deaths: final data for 2015. National Vital Statistics Reports; vol 6, no. 6. National Center for Health Statistics, Hyattsville, MD: https://www.cdc.gov/nchs/data/nvsr/nvsr66/nvsr66_06.pdf. [Google Scholar]
  3. [3]Diekema DJ, Beekmann SE, Chapin KC, Morel KA, Munson E, Doern GV. 2003. Epidemiology and outcome of nosocomial and community-onset bloodstream infection. J Clin Microbiol 41:3655–3660. doi: 10.1128/JCM.41.8.3655-3660.2003. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  4. [4]Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. 2000. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118:146–155. doi: 10.1378/chest.118.1.146. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  5. [5]MacArthur RD, Miller M, Albertson T, Panacek E, Johnson D, Teoh L, Barchuk W. 2004. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis 38:284–288. doi: 10.1086/379825. [DOI] [PubMed] [Google Scholar] · DOI
  6. [6]Timbrook TT, Morton JB, McConeghy KW, Caffrey AR, Mylonakis E, LaPlante KL. 2017. The effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysis. Clin Infect Dis 64:15–23. doi: 10.1093/cid/ciw649. [DOI] [PubMed] [Google Scholar] · DOI
  7. [7]Centers for Disease Control and Prevention. 2011. CDC strategic priorities for combating antimicrobial resistance. Centers for Disease Control and Prevention, Atlanta, GA: https://www.cdc.gov/drugresistance/pdf/cdc-priorities-combating-ar-infections-report-workshop.pdf. [Google Scholar]
  8. [8]Centers for Disease Control and Prevention. 2015. National action plan for combating antibiotic-resistant bacteria. Centers for Disease Control and Prevention, Atlanta, GA: https://www.cdc.gov/drugresistance/pdf/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf. [Google Scholar]
  9. [9]Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP, Raad II, Rijnders BJA, Sherertz RJ, Warren DK. 2009. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 49:1–45. doi: 10.1086/599376. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
  10. [10]Chotiprasitsakul D, Han JH, Cosgrove SE, Harris AD, Lautenbach E, Conley AT, Tolomeo P, Wise J, Tamma PD, Antibacterial Resistance Leadership Group. 2018. Comparing the outcomes of adults with Enterobacteriaceae bacteremia receiving short-course versus prolonged-course antibiotic therapy in a multicenter, propensity score-matched cohort. Clin Infect Dis 66:172–177. doi: 10.1093/cid/cix767. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  11. [11]Nelson AN, Justo JA, Bookstaver PB, Kohn J, Albrecht H, Al-Hasan MN. 2017. Optimal duration of antimicrobial therapy for uncomplicated Gram-negative bloodstream infections. Infection 45:613–620. doi: 10.1007/s15010-017-1020-5. [DOI] [PubMed] [Google Scholar] · DOI
  12. [12]Daneman N, Rishu AH, Xiong W, Bagshaw SM, Dodek P, Hall R, Kumar A, Lamontagne F, Lauzier F, Marshall J, Martin CM, McIntyre L, Muscedere J, Reynolds S, Stelfox HT, Cook DJ, Fowler RA, Canadian Critical Care Trials Group. 2016. Duration of antimicrobial treatment for bacteremia in Canadian critically ill patients. Crit Care Med 44:256–264. doi: 10.1097/CCM.0000000000001393. [DOI] [PubMed] [Google Scholar] · DOI
  13. [13]Kollef MH, Chastre J, Clavel M, Restrepo MI, Michiels B, Kaniga K, Cirillo I, Kimko H, Redman R. 2012. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 16:R218. doi: 10.1186/cc11862. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  14. [14]Doi A, Morimoto T, Iwata K. 2018. Shorter duration of antibiotic treatment for acute bacteraemic cholangitis with successful biliary drainage: a retrospective cohort study. Clin Microbiol Infect 24:1184–1189. doi: 10.1016/j.cmi.2018.01.021. [DOI] [PubMed] [Google Scholar] · DOI
  15. [15]Havey TC, Fowler RA, Pinto R, Elligsen M, Daneman N. 2013. Duration of antibiotic therapy for critically ill patients with bloodstream infections: a retrospective cohort study. Can J Infect Dis Med Microbiol 24:129–137. doi: 10.1155/2013/141989. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  16. [16]Pereira JM, Goncalves-Pereira J, Ribeiro O, Baptista JP, Froes F, Paiva JA. 2018. Impact of antibiotic therapy in severe community-acquired pneumonia: data from the Infauci study. J Crit Care 43:183–189. doi: 10.1016/j.jcrc.2017.08.048. [DOI] [PubMed] [Google Scholar] · DOI
  17. [17]Runyon BA, McHutchison JG, Antillon MR, Akriviadis EA, Montano AA. 1991. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology 100:1737–1742. doi: 10.1016/0016-5085(91)90677-D. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  18. [18]Siegel RE, Alicea M, Lee A, Blaiklock R. 1999. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study. Am J Ther 6:217–222. doi: 10.1097/00045391-199907000-00007. [DOI] [PubMed] [Google Scholar] · DOI
  19. [20]Giannella M, Pascale R, Toschi A, Ferraro G, Graziano E, Furii F, Bartoletti M, Tedeschi S, Ambretti S, Lewis RE, Viale P. 2018. Treatment duration for Escherichia coli bloodstream infection and outcomes: retrospective single-centre study. Clin Microbiol Infect 24:1077–1083. doi: 10.1016/j.cmi.2018.01.013. [DOI] [PubMed] [Google Scholar] · DOI
  20. [21]Mercuro NJ, Stogsdill P, Wungwattana M. 2018. Retrospective analysis comparing oral stepdown therapy for enterobacteriaceae bloodstream infections: fluoroquinolones versus beta-lactams. Int J Antimicrob Agents 51:687–692. doi: 10.1016/j.ijantimicag.2017.12.007. [DOI] [PubMed] [Google Scholar] · DOI
  21. [22]Swamy S, Sharma R. 2016. Duration of treatment of Gram-negative bacteremia: are shorter courses of antimicrobial therapy feasible? Infect Dis Clin Pract 24:155–160. doi: 10.1097/IPC.0000000000000362. [DOI] [Google Scholar] · DOI
  22. [23]Sandberg T, Skoog G, Hermansson AB, Kahlmeter G, Kuylenstierna N, Lannergard A, Otto G, Settergren B, Ekman GS. 2012. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet 380:484–490. doi: 10.1016/S0140-6736(12)60608-4. [DOI] [PubMed] [Google Scholar] · DOI
  23. [24]Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A, Reuning-Scherer J, Church DA. 2000. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA 283:1583–1590. doi: 10.1001/jama.283.12.1583. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  24. [25]Uno S, Hase R, Kobayashi M, Shiratori T, Nakaji S, Hirata N, Hosokawa N. 2017. Short-course antimicrobial treatment for acute cholangitis with Gram-negative bacillary bacteremia. Int J Infect Dis 55:81–85. doi: 10.1016/j.ijid.2016.12.018. [DOI] [PubMed] [Google Scholar] · DOI
  25. [26]Meropol SB, Chan KA, Chen Z, Finkelstein JA, Hennessy S, Lautenbach E, Platt R, Schech SD, Shatin D, Metlay JP. 2008. Adverse events associated with prolonged antibiotic use. Pharmacoepidemiol Drug Saf 17:523–532. doi: 10.1002/pds.1547. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  26. [27]Barbosa TM, Levy SB. 2000. The impact of antibiotic use on resistance development and persistence. Drug Resist Updat 3:303–311. doi: 10.1054/drup.2000.0167. [DOI] [PubMed] [Google Scholar] · DOI
  27. [28]Cantón R, Morosini MI. 2011. Emergence and spread of antibiotic resistance following exposure to antibiotics. FEMS Microbiol Rev 35:977–991. doi: 10.1111/j.1574-6976.2011.00295.x. [DOI] [PubMed] [Google Scholar] · DOI
  28. [29]Ventola CL. 2015. The antibiotic resistance crisis: part 1: causes and threats. P T 40:277–283. [PMC free article] [PubMed] [Google Scholar]
  29. [30]Chong YP, Moon SM, Bang KM, Park HJ, Park SY, Kim MN, Park KH, Kim SH, Lee SO, Choi SH, Jeong JY, Woo JH, Kim YS. 2013. Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study. Antimicrob Agents Chemother 57:1150–1156. doi: 10.1128/AAC.01021-12. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  30. [31]Daneman N, Shore K, Pinto R, Fowler R. 2011. Antibiotic treatment duration for bloodstream infections in critically ill patients: a national survey of Canadian infectious diseases and critical care specialists. Int J Antimicrob Agents 38:480–485. doi: 10.1016/j.ijantimicag.2011.07.016. [DOI] [PubMed] [Google Scholar] · DOI
  31. [32]Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. 2012. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother 67:742–748. doi: 10.1093/jac/dkr508. [DOI] [PubMed] [Google Scholar] · DOI
  32. [33]Hanon FX, Monnet DL, Sorensen TL, Molbak K, Pedersen G, Schonheyder H. 2002. Survival of patients with bacteraemia in relation to initial empirical antimicrobial treatment. Scand J Infect Dis 34:520–528. doi: 10.1080/00365540110080827. [DOI] [PubMed] [Google Scholar] · DOI
  33. [35]Nielsen SL, Lassen AT, Gradel KO, Jensen TG, Kolmos HJ, Hallas J, Pedersen C. 2015. Bacteremia is associated with excess long-term mortality: a 12-year population-based cohort study. J Infect 70:111–126. doi: 10.1016/j.jinf.2014.08.012. [DOI] [PubMed] [Google Scholar] · DOI
  34. [36]Kutob LF, Justo JA, Bookstaver PB, Kohn J, Albrecht H, Al-Hasan MN. 2016. Effectiveness of oral antibiotics for definitive therapy of Gram-negative bloodstream infections. Int J Antimicrob Agents 48:498–503. doi: 10.1016/j.ijantimicag.2016.07.013. [DOI] [PubMed] [Google Scholar] · DOI
  35. [37]Wells G, Shea B, O’Connell J, Robertson J. 2011. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. [Google Scholar]
  36. [38]The Nordic Cochrane Centre. 2014. Review Manager (RevMan). Version 5.3. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark. [Google Scholar]
  37. [39]Ryan R, Cochrane Consumers and Communication Review Group. 2016. Heterogeneity and subgroup analyses in Cochrane Consumers and Communication Group reviews: planning the analysis at protocol stage. Cochrane Consumers and Communication, London, United Kingdom: http://cccrg.cochrane.org/sites/cccrg.cochrane.org/files/public/uploads/heterogeneity_subgroup_analyses_revising_december_1st_2016.pdf. [Google Scholar]
  38. [40]Mantel N, Haenszel W. 1959. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748. [PubMed] [Google Scholar]
  39. [41]DerSimonian R, Laird N. 1986. Meta-analysis in clinical trials. Control Clin Trials 7:177–188. doi: 10.1016/0197-2456(86)90046-2. [DOI] [PubMed] [Google Scholar] · DOI · Paper page

Cited by

Sorted by citations

Authors
Tansarli, G. S., Andreatos, N., Pliakos, E. E., & Mylonakis, E.
Affiliations
Brown University (US)
ORCID
Venue
Antimicrobial Agents and Chemotherapy
Publisher
American Society for Microbiology
Published
2019-05
Volume
63
Issue
5
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
DOI
10.1128/aac.02495-18
PMC
PMC6496097
OpenAlex
W2916145574
Cited by
56
References
2
Citations by year
2026: 2 · 2025: 12 · 2024: 5 · 2023: 3 · 2022: 11 · 2021: 16 · 2020: 4 · 2019: 3
FWCI
1.09
Type
journal article
Language
en
Open access
Licence
journals.asm.org/non-commercial-tdm-license (tdm)
Locations
  • Antimicrobial Agents and Chemotherapy (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Antibiotics Pharmacokinetics and Efficacy
  • Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Antibiotic Use and Resistance
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Antibiotic Resistance in Bacteria
Keywords
bacteremia, Enterobacteriaceae, antibiotic duration, short-course antibiotic therapy, clinical outcomes, length of hospital stay
MeSH terms
Anti-Bacterial Agents, Enterobacteriaceae, Humans, Bacteremia, Sepsis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review